- Home
- FTRE vs ALVO Comparison
FTRE vs ALVO Comparison
Compare FTRE & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTRE | ALVO |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTRE | ALVO |
|---|---|---|
| Price | $10.39 | $3.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $15.39 | $9.25 |
| AVG Volume (30 Days) | ★ 2.1M | 573.5K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,723,400,000.00 | N/A |
| Revenue This Year | N/A | $20.22 |
| Revenue Next Year | $2.96 | $37.22 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $3.97 | $3.65 |
| 52 Week High | $18.67 | $11.85 |
Technical Indicators
Market Signals| Indicator | FTRE | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 32.76 | 29.58 |
| Support Level | $9.35 | N/A |
| Resistance Level | $11.41 | $5.46 |
| Average True Range (ATR) | 1.01 | 0.24 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 57.60 | 20.62 |
Price Performance
Historical ComparisonAbout FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.